{"id":"amcinonide","rwe":[],"_fda":{"id":"86f4ed99-b557-44f7-966d-4f187e89784c","set_id":"83da75e7-e182-4a6c-ac0f-50d99971ebde","openfda":{"nui":["N0000175576","N0000175450"],"upc":["0373308407605"],"unii":["423W026MA9"],"route":["TOPICAL"],"rxcui":["197328"],"spl_id":["86f4ed99-b557-44f7-966d-4f187e89784c"],"brand_name":["Amcinonide"],"spl_set_id":["83da75e7-e182-4a6c-ac0f-50d99971ebde"],"package_ndc":["73308-407-60"],"product_ndc":["73308-407"],"generic_name":["AMCINONIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMCINONIDE"],"pharm_class_epc":["Corticosteroid [EPC]"],"pharm_class_moa":["Corticosteroid Hormone Receptor Agonists [MoA]"],"manufacturer_name":["Ayurax, LLC"],"application_number":["ANDA076096"],"is_original_packager":[true]},"version":"3","overdosage":["OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS )."],"description":["DESCRIPTION: The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Each gram of Amcinonide Ointment USP, 0.1% contains 1 mg of the active steroid amcinonide in a specially formulated base composed of Benzyl Alcohol 2%, (wt/wt) as preservative, White Petrolatum, USP, Emulsifying Wax, and Antioxidant Blend (Propylene Glycol, Butylated Hydroxyanisole, Propyl Gallate and Citric Acid). Chemically, amcinonide is: Pregna-1,4-diene-3,20-dione,21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11β, 16α). Chemical Formula"],"precautions":["PRECAUTIONS: General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria in some patients. Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests. If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute with a less potent steroid. Recovery of HPA-axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS- Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. The products are not for ophthalmic use. Information for the Patient : Patients using topical corticosteroids should receive the following information and instructions: 1.This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped, as to be occlusive, unless directed by the physician. 4. Patients should report any signs of local adverse reactions, especially those that occur under occlusive dressings. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests : The following tests may be helpful in evaluating the HPA-axis suppression: Urinary free-cortisol test, ACTH stimulation test. Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids or their effect on fertility. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers : It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use : Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature patients because of a higher ratio of skin surface area to body weight. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients."],"how_supplied":["HOW SUPPLIED: Amcinonide Ointment USP, 0.1% (1 mg/g) is supplied as follows: NDC 73308-407-60; 60 gram tubes Store at controlled room temperature 15° - 30°C (59° - 86°F) (see USP). Manufactured for: Ayurax, LLC Fairhope, AL 36532 Rev. 09/23"],"pediatric_use":["Pediatric Use : Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature patients because of a higher ratio of skin surface area to body weight. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients."],"effective_time":"20251006","nursing_mothers":["Nursing Mothers : It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests : The following tests may be helpful in evaluating the HPA-axis suppression: Urinary free-cortisol test, ACTH stimulation test."],"adverse_reactions":["ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Pharm-Olam at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."],"general_precautions":["General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia and glucosuria in some patients. Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests. If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute with a less potent steroid. Recovery of HPA-axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS- Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. The products are not for ophthalmic use."],"teratogenic_effects":["Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile."],"indications_and_usage":["INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."],"information_for_patients":["Information for the Patient : Patients using topical corticosteroids should receive the following information and instructions: 1.This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped, as to be occlusive, unless directed by the physician. 4. Patients should report any signs of local adverse reactions, especially those that occur under occlusive dressings. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings."],"spl_unclassified_section":["Rx only NOT FOR OPHTHALMIC USE. FOR DERMATOLOGIC USE ONLY."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION: Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition. Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted."],"spl_product_data_elements":["Amcinonide amcinonide AMCINONIDE AMCINONIDE PETROLATUM BENZYL ALCOHOL BUTYLATED HYDROXYANISOLE PROPYL GALLATE CITRIC ACID MONOHYDRATE PROPYLENE GLYCOL"],"package_label_principal_display_panel":["PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 G TUBE NDC 73308-407-60 Ayurax LLC AMCINONIDE OINTMENT USP, 0.1% Rx only NOT FOR OPHTHALMIC USE. FOR DERMATOLOGIC USE ONLY. NET WT 60 grams PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 G CONTAINER","PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 G CARTON: NDC 73308-407-60 Rx only Ayurax, LLC AMCINONIDE OINTMENT USP, 0.1% NOT FOR OPHTHALMIC USE. FOR DERMATOLOGIC USE ONLY. NET WT 60 grams PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 G CARTON"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids or their effect on fertility. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"D07AC11","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Lotion","category":"form"},{"label":"Ointment","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Contact dermatitis","category":"indication"},{"label":"Discoid lupus erythematosus","category":"indication"},{"label":"Eruption of skin","category":"indication"},{"label":"Granuloma annulare","category":"indication"},{"label":"Lichen simplex chronicus","category":"indication"},{"label":"Astellas","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"skin atrophy","drugRate":"reported","severity":"unknown"},{"effect":"miliaria","drugRate":"reported","severity":"unknown"},{"effect":"striations","drugRate":"reported","severity":"unknown"},{"effect":"secondary infection","drugRate":"reported","severity":"serious"},{"effect":"maceration of the skin","drugRate":"reported","severity":"serious"},{"effect":"allergic contact dermatitis","drugRate":"reported","severity":"serious"},{"effect":"perioral dermatitis","drugRate":"reported","severity":"serious"},{"effect":"hypopigmentation","drugRate":"reported","severity":"mild"},{"effect":"hypertrichosis","drugRate":"reported","severity":"mild"},{"effect":"acneiform eruptions","drugRate":"reported","severity":"mild"},{"effect":"folliculitis","drugRate":"reported","severity":"mild"},{"effect":"dryness","drugRate":"reported","severity":"mild"},{"effect":"irritation","drugRate":"reported","severity":"mild"},{"effect":"itching","drugRate":"reported","severity":"mild"},{"effect":"burning","drugRate":"reported","severity":"mild"}],"contraindications":["Atrophoderma","Bilateral cataracts","Diabetes mellitus type 1","Diabetes mellitus type 2","Glaucoma","Peripheral vascular disease","Tuberculosis of skin"],"specialPopulations":{"Pregnancy":"Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the risk.","Paediatric use":"Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA-axis suppression and Cushings syndrome than mature patients because of larger skin surface area to body weight ratio.Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushings syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation."}},"trials":[],"aliases":[],"company":"Astellas Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMCINONIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:43:26.446109+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Amcinonide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:43:33.411266+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:43:31.923634+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMCINONIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:43:32.263486+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:43:25.327279+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:43:25.327309+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:43:25.327316+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:43:33.411200+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200732/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:43:33.070121+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076096","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:43:25.327320+00:00"}},"allNames":"cyclocort","offLabel":[],"synonyms":["amcinonide","amciderm","amcinonid","cyclocort"],"timeline":[{"date":"1979-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ASTELLAS to Astellas"},{"date":"1979-10-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astellas)"},{"date":"1988-06-13","type":"positive","source":"FDA Orange Book","milestone":"Cyclocort approved — 0.1%"},{"date":"2003-03-19","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Cyclocort (AMCINONIDE) is a corticosteroid medication developed by Astellas, targeting the glucocorticoid receptor. It is a small molecule drug approved by the FDA in 1979 for various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Cyclocort is off-patent, with multiple generic manufacturers available. As a corticosteroid, it works by reducing inflammation and suppressing the immune system. Key safety considerations include potential skin thinning and increased risk of infections.","brandName":"Cyclocort","ecosystem":[{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"baricitinib","slug":"baricitinib","company":"Eli Lilly And Co"}],"globalPrevalence":204050000},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"},{"name":"betamethasone","slug":"betamethasone","company":""}],"globalPrevalence":324000000},{"indication":"Discoid lupus erythematosus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"}],"globalPrevalence":2400000},{"indication":"Eruption of skin","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"},{"name":"betamethasone","slug":"betamethasone","company":""}],"globalPrevalence":null},{"indication":"Granuloma annulare","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"},{"name":"betamethasone","slug":"betamethasone","company":""}],"globalPrevalence":null},{"indication":"Lichen simplex chronicus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"}],"globalPrevalence":null},{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"apremilast","slug":"apremilast","company":"Celgene Corp"}],"globalPrevalence":125000000},{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"}],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Cyclocort (AMCINONIDE) is a synthetic corticosteroid that acts as a potent inhibitor of phospholipase A2, thereby reducing the production of pro-inflammatory mediators and suppressing the immune response."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Amcinonide","title":"Amcinonide","extract":"Amcinonide is a topical glucocorticoid used to treat itching, redness and swelling associated with several dermatologic conditions such as atopic dermatitis and allergic contact dermatitis.\nAmcinonide can also be classified as a multi-functional small molecule corticosteroid, which has been approved by the FDA and is currently marketed as an ointment, lotion, or cream. It acts as both a transcription factor for responses to glucocorticoids and modulator for other transcription factors while also regulating phospholipase A2 activity.","wiki_history":"==History==\nAmcinonide was first developed in the United Kingdom in the 1960s and 1970s before being patented by the American Cyanamid company.  Lederle Laboratories, most famous for the discovery of the antibacterial tetracycline drug class, began to manufacture of Amcinonide before being acquired by Cyanamid.  In 1994, American Cyanamid and its Lederle Lab division was purchased by American Home Products (AHP) before eventually changing the company's name to Wyeth Pharmaceuticals in 2002.  Wyeth Pharma was eventually purchased by rival Pfizer in 2009 for $68 billion although the manufacture of Amcinonide has since been discontinued by the company.\n\n===Research & Clinical Trials===\nAmcinonide is produced from the reaction of 16α,17α-Cyciopentylidenedioxy-9α-fluoro-11β,21-dihydroxy-1,4pregnadiene-3,20-dione and acetic anhydride in which 11.1g and 5.5mL, respectively, of each reactant are consumed to produce 7.0g of pure product.  The outcomes of relevant trials are included below.\n\nOne of the initial clinical studies into Amcinonide, conducted by Woodford & Barry, 1979, compared topical applications Amcinonide to Triamcinolone Acetonide.  Specifically, 0.1% strength preparations of each compound were tested against 0.025% Synalar Gel and 0.1% Betnovate Cream using a vasoconstrictor assay to determine bioavailability and anti-inflammatory effects.  All formulations had similar bioavailability profiles with the peak of the curve coming approximately 12 hours after topical administration and covering with an occlusive dressing.  Concluding, the study found Amcinonide cream to be the most effective with the highest bio-activity and area under the curve (pharmacokinetics).\n\nA French study by Binet et al., 1979, compared 0.1% Amcinonide ointment to equal strength Fluocinonide ointment, a similar corticosteroid already on the market.  A double-blind comparative analysis was conducted to determine if Amcinonide was bioequivalent for the treatment of psoriasis and eczema.  E"},"commercial":{"launchDate":"1979","_launchSource":"DrugCentral (FDA 1979-10-18, ASTELLAS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/150","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMCINONIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Amcinonide","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:40:02.933731","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:43:35.791836+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"desoximetasone","drugSlug":"desoximetasone","fdaApproval":"1977-02-28","patentExpiry":"Sep 1, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluocinolone acetonide","drugSlug":"fluocinolone-acetonide","fdaApproval":"1963-02-15","patentExpiry":"Nov 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fludroxycortide","drugSlug":"fludroxycortide","fdaApproval":"1963-03-19","relationship":"same-class"},{"drugName":"fluocinonide","drugSlug":"fluocinonide","fdaApproval":"1971-06-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"budesonide","drugSlug":"budesonide","fdaApproval":"1994-02-14","patentExpiry":"Sep 9, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diflorasone diacetate","drugSlug":"diflorasone-diacetate","fdaApproval":"1977-09-14","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mometasone furoate","drugSlug":"mometasone-furoate","fdaApproval":"1987-04-30","patentExpiry":"Oct 3, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-class"},{"drugName":"hydrocortisone aceponate","drugSlug":"hydrocortisone-aceponate","fdaApproval":"","relationship":"same-class"},{"drugName":"fluticasone furoate","drugSlug":"fluticasone-furoate","fdaApproval":"2007-04-27","patentExpiry":"Oct 15, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluticasone propionate","drugSlug":"fluticasone-propionate","fdaApproval":"1990-12-14","patentExpiry":"Sep 26, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednicarbate","drugSlug":"prednicarbate","fdaApproval":"1991-09-23","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"difluprednate","drugSlug":"difluprednate","fdaApproval":"2008-06-23","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ulobetasol propionate","drugSlug":"ulobetasol-propionate","fdaApproval":"1990-12-17","relationship":"same-class"}],"genericName":"amcinonide","indications":{"approved":[{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":"adults and children 2 years of age and older","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":"adults and children 2 years of age and older","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":"adults and children 2 years of age and older","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","eligibility":"adults and children 2 years of age and older","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA","eligibility":"adults and children 2 years of age and older"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Astellas","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"desoximetasone","brandName":"desoximetasone","genericName":"desoximetasone","approvalYear":"1977","relationship":"same-class"},{"drugId":"fluocinolone-acetonide","brandName":"fluocinolone acetonide","genericName":"fluocinolone acetonide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fludroxycortide","brandName":"fludroxycortide","genericName":"fludroxycortide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fluocinonide","brandName":"fluocinonide","genericName":"fluocinonide","approvalYear":"1971","relationship":"same-class"},{"drugId":"budesonide","brandName":"budesonide","genericName":"budesonide","approvalYear":"1994","relationship":"same-class"},{"drugId":"diflorasone-diacetate","brandName":"diflorasone diacetate","genericName":"diflorasone diacetate","approvalYear":"1977","relationship":"same-class"},{"drugId":"mometasone-furoate","brandName":"mometasone furoate","genericName":"mometasone furoate","approvalYear":"1987","relationship":"same-class"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-class"},{"drugId":"hydrocortisone-aceponate","brandName":"hydrocortisone aceponate","genericName":"hydrocortisone aceponate","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Lotion, Ointment","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"Amcinonide"},{"form":"LOTION","route":"TOPICAL","productName":"amcinonide"},{"form":"OINTMENT","route":"TOPICAL","productName":"Amcinonide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146271","MMSL":"222","NDDF":"002202","UNII":"423W026MA9","VUID":"4017920","CHEBI":"CHEBI:31199","VANDF":"4017920","INN_ID":"3755","RXNORM":"17652","UMLSCUI":"C0051556","chemblId":"CHEMBL1200732","ChEMBL_ID":"CHEMBL1200732","KEGG_DRUG":"D01387","DRUGBANK_ID":"DB00288","PUBCHEM_CID":"443958","SNOMEDCT_US":"420859004","IUPHAR_LIGAND_ID":"7060","MESH_SUPPLEMENTAL_RECORD_UI":"C012716"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1979-","companyName":"Astellas","relationship":"Original Developer"}],"publicationCount":51,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"D07AC11","allCodes":["D07AC11"]},"biosimilarFilings":[],"originalDeveloper":"Astellas","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Genus","Genus Lifesciences","Solubiomix","Taro Pharm Inds"],"status":"approved","companyName":"Astellas","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"1979","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:43:35.791836+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":false,"score":2}}